Literature DB >> 10102615

CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.

J M Fang1, W G Finn, J W Hussong, C L Goolsby, A R Cubbon, D Variakojis.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a common morphologic term for a biologically diverse group of lymphomas. The chromosome translocation, t(14;18)(q32;q21), and its associated bcl-2 gene rearrangement are generally associated with follicular lymphomas. Some investigators, however, proposed that the presence of the t(14;18) in DLBCL suggests a possible follicle center cell origin and might correlate with a higher relapse rate after therapy. The CD10 antigen is expressed in a majority of follicular lymphomas but is also seen occasionally in DLBCLs. In this study, we examined 26 DLBCLs for CD10 expression by flow cytometric analysis and tested them for the t(14;18)(q32;q21) major breakpoint region by a polymerase chain reaction-based method. bcl-2 protein expression was analyzed by an immunoperoxidase method. Of the 26 DLBCLs, 9 (35%) were CD10 positive. bcl-2 protein was expressed in 7 (78%) of 9 CD10-positive cases and in 9 (53%) of 17 CD10-negative cases (P = .4). The t(14; 18) translocation was present in 6 (67%) of 9 CD10-positive cases but in only 2 (17%) of 12 CD10-negative cases (P = .03). Five cases did not yield amplifiable DNA for analysis. In summary, no difference in bcl-2 protein expression was seen in CD10-positive versus CD10-negative DLBCLs, but CD10-positive DLBCLs were significantly more likely than CD10-negative DLBCLs to harbor the t(14;18) translocation. This suggests that CD10 might be a marker of follicle center cell origin in DLBCL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102615

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

1.  Follicular lymphoma in Osaka, Japan: histological features and chronological change.

Authors:  Hajime Miyazato; Shin-ichi Nakatsuka; Itsuko Miyanaga; Hitoshi Hanamoto; Yoichi Tatsumi; Mitsuhiro Matsuda; Yasuhiro Maeda; Akihisa Kanamaru; Katsuyuki Aozasa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 2.  CD10 expression in diffuse large B-cell lymphomas does not influence survival.

Authors:  Bettina Fabiani; Alain Delmer; Eric Lepage; Catherine Guettier; Tony Petrella; Josette Brière; Anne-Marie Penny; Marie-Christine Copin; Jacques Diebold; Felix Reyes; Philippe Gaulard; Thierry J Molina
Journal:  Virchows Arch       Date:  2004-10-27       Impact factor: 4.064

3.  Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma.

Authors:  Hong-Wei Zhang; Niu-Liang Cheng; Zhen-Wen Chen; Jin-Fen Wang; Su-Hong Li; Wei Bai
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

4.  R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.

Authors:  Xiao-Hui He; Bo Li; Sheng Yang; Ning Lu; Xun Zhang; Shuang-Mei Zou; Ye-Xiong Li; Yong-Wen Song; Shan Zheng; Mei Dong; Sheng-Yu Zhou; Jian-Liang Yang; Peng Liu; Chang-Gong Zhang; Yan Qin; Feng-Yi Feng; Yuan-Kai Shi
Journal:  Chin J Cancer       Date:  2012-05-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.